1. Field of the Invention
The invention relates to a threaded syringe, and more particularly, the invention relates to a threaded syringe with a quick stop.
2. Brief Description of the Related Art
The delivery of fluid compositions which solidify in vivo is particularly useful for a variety of reasons including treatment of blood vessels, tumors, aneurysms, arteriovenous malformations (“AVMs”), arteriovenous fistula (“AVF”), uncontrolled bleeding and the like, as well as in the sterilization of mammals by blocking the vas deferens or fallopian tubes, in the treatment of urinary incontinence by the addition of a bulking agent to the periurethral tissue, and the like.
Delivery of such compositions is preferably accomplished via catheter techniques which permit the selective placement of the catheter at the delivery site. For example, recent advancements in catheter technology as well as in angiography now permit neuro endovascular intervention including the treatment of otherwise inoperable lesions. Specifically, development of microcatheters and guidewires capable of providing access to vessels as small as 1 millimeter in diameter allows for the endovascular treatment of many lesions.
Catheter delivery for in vivo solid mass formation can employ fluid compositions which comprise a solvent such as ethanol, dimethylsulfoxide (“DMSO”), or aqueous solutions of ethanol or DMSO, a biocompatible water insoluble polymer, and a water insoluble contrast agent. Preferably, however, the solvent is non-aqueous in order to maximize the amount of biocompatible water insoluble polymer which can be dissolved therein.
In practice, the catheter tip is directed to the vascular or other delivery site by use of conventional visualization techniques such as fluoroscopy, and the like which allow the clinician to visualize the catheter tip. After placement of the catheter, the composition is introduced into the catheter and delivered to this site. Upon delivery, the solvent dissipates into the blood, fluid, or tissue and the water insoluble polymer precipitates to form a coherent mass which solidifies in vivo.
One use of this liquid embolic polymer composition is in minimally invasive procedures for treating intracranial aneurysms. The use of liquid embolic compositions addresses the problems with the known aneurysm treatment methods, such as surgical clipping and coil delivery, and involves the endovascular injection of the liquid embolic composition which solidifies in the aneurysm to occlude the aneurysm. Typically, the liquid embolic composition will include a water insoluble, biocompatible, non-biodegradable polymer dissolved in a biocompatible solvent. Once the liquid embolic composition is injected into the aneurysm, the biocompatible solvent dissipates into the blood and the polymer solidifies to occlude the blood flow into the aneurysm. These liquid embolic compositions preferably include a radiopaque material which allows the physician to view the embolization procedure by fluoroscopy or other visualization techniques.
Due to limitations of the conventional catheter delivery systems for delivery of these liquid embolic compositions, it was difficult to deliver compositions of a biocompatible polymer, a biocompatible solvent, and a biocompatible contrast agent including greater than 8 weight percent polymer based on the entire weight of the compositions, through a micro catheter with a conventional syringe because of the viscosity of the composition. However, in some instances it is desirable to deliver higher viscosity embolic compositions, for example compositions containing more than 8 weight percent of a polymer. Higher viscosity embolic compositions are described in U.S. patent application Ser. No. 09/574,379 entitled “Novel High Viscosity Embolizing Compositions,” filed May 19, 2000, which is incorporated herein by reference in its entirety. These higher viscosity embolic compositions are generally easier to position within an aneurysm. The higher viscosity may also help to prevent portions of the polymer from being separated from polymer mass and being carried away in the blood stream where the polymer can occlude an undesired vascular location.
Accordingly, it would be desirable to provide a syringe for delivery of high viscosity liquids through small lumens.
It would also be desirable to provide a syringe with a tactile or audible indication of delivery which allows the clinician to monitor delivery without viewing the syringe.
It would also be desirable to provide a threaded syringe with a quick stop mechanism for releasing pressure on the delivered fluid to rapidly stop delivery of the fluid.
According to one aspect of the present invention, a syringe includes a syringe barrel having a distal delivery orifice and a proximal end, a sliding member positioned on the proximal end of the syringe barrel, the sliding member having a first threaded hole and a second hole and being slidable on the syringe barrel between a first position at which the first threaded hole is aligned with the syringe barrel and a second position at which the second hole is aligned with the syringe barrel, and a threaded plunger for delivery of a fluid from the syringe barrel through the delivery orifice.
According to another aspect of the present invention, a method for embolizing a vascular site includes the steps of positioning the distal end of a delivery catheter in said vascular site, connecting a threaded syringe containing a liquid embolic composition to a distal end of the delivery catheter, rotating a plunger of the threaded syringe to inject the liquid embolic composition to the vascular site in a precisely controllable manner, and releasing pressure on the liquid embolic composition by disengaging threads of the plunger from a barrel of the syringe.
According to a further aspect of the present invention, a syringe includes a syringe barrel having a distal delivery orifice and a proximal end, an internally threaded member at the proximal end of the syringe barrel, a threaded plunger receivable in the internally threaded member for delivery of a fluid from the syringe barrel through the delivery orifice, the threaded plunger having a longitudinal groove, and a spring element for engaging the longitudinal groove to provide a tactile or audible indication of fluid delivery.
The present invention provides advantages of a syringe which can be used to deliver a high viscosity composition. The invention may also be used as either a conventional syringe or a threaded syringe. The present invention may also provide a quick stop mechanism for stopping the delivery of a high viscosity composition. The present invention may also provide the advantage of a tactile or audible indication of delivery.
The invention will now be described in greater detail with reference to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:
A syringe according to the present invention provides a mechanism by which a clinician can deliver a viscous fluid through relatively small lumens and can obtain tactile or audible feedback of delivery. According to one aspect of the invention, the syringe can be used either as a conventional syringe or as a threaded syringe. The threaded syringe allows for delivery of more viscous fluids with less force and/or allows for more controlled delivery. The threaded syringe is particularly useful for delivery of fluids through small diameter lumens such as micro catheters. Micro catheters typically have lumen diameters of about 0.008 inches to about 0.018 inches.
The sliding member 14 is shown in further detail in
The sliding member 14 also includes a spring element 40 shown in
The threaded plunger 16 as shown in
The syringe assembly 10 according to the present invention provides a mechanism by which the syringe can be filled with fluid in the normal fashion with the plunger shaft 50 positioned in the unthreaded bore 30 of the sliding member 14. After filling, the sliding member 14 can be slid to a second position at which the plunger shaft 50 is positioned in the threaded bore 28 and the threaded plunger is used for slow, controlled injection of fluid by rotation of the plunger. In order to slide the sliding member 14 from the first position to the second position, the plunger 16 should be positioned with the unthreaded portion 54 of the plunger shaft 50 located at the intersection of the bores 28, 30 in the sliding member 14. The groove 60 and spring element 40 provide a tactile and/or audible indication or click upon each revolution of the threaded plunger 16. This allows the clinician to determine the amount of fluid injected without looking at the syringe graduation lines.
The sliding member 14 is also used as a quick stop mechanism. The sliding member 14 provides a pressure relief mechanism by which the injection pressure can be removed from the material in the syringe barrel 12 stopping injection of the material. For example, when a liquid embolic composition is delivered to a vascular site by the syringe 10 according to the present invention, the composition will continue to be delivered for a time period of about 30 seconds after the rotation of the plunger handle 48 has been halted. This is due to the back pressure in the syringe and catheter. The sliding member 14 allows the pressure on the composition to be immediately removed by moving the sliding member to a position at which the unthreaded bore 30 is aligned with the plunger 16. The use of the sliding member 14 reduces the time between the time at which the rotation of the handle 48 is stopped and the time at which material delivery from the distal end of the catheter stops to about 1 second. This time may be called the bleed out time. Thus, the bleed out time is reduced by use of the quick stop from more than 10 seconds to less than 5 seconds.
The sliding member 114 is shown in further detail in
The sliding member 114 is preferably provided with a thumb pad 170 at each side of the sliding member for ease of movement of the sliding member by the thumb or other fingers of the clinician. The thumb pads 170, one of which is shown in
The sliding member 114 also includes a spring element 140 shown in
The threaded plunger 116, as shown in
The syringe according to the present invention is particularly designed for controlled delivery of high viscosity compositions. High viscosity compositions include compositions having viscosities of about 150 to about 2000 centistokes. The syringe of the present invention may be used for delivery of a variety of compositions including liquid embolic compositions, any oncological drug, contrast agents, and the like.
High viscosity liquid embolic compositions are defined as compositions containing more than eight weight percent of a polymer, and preferably with at least twelve percent polymer as described in U.S. patent application Ser. No. 09/574,379, entitled “Novel High Viscosity Embolizing Compositions,” filed May 19, 2000. It should be understood that the syringe may also be used for delivering other high viscosity fluid compositions or for delivery of fluids where it is important to provide carefully controlled liquid injection.
Examples of liquid embolic compositions and delivery systems are described in U.S. Pat. Nos. 5,830,178 and 5,695,480 which are incorporated herein by reference in their entirety.
The threaded syringes 10, 110 according to the present invention, are particularly designed for use in delivery of a high viscosity liquid embolic composition to a vascular site. The embolic composition is loaded into the syringe by positioning the sliding member with the unthreaded bore aligned with the plunger and withdrawing the plunger to draw the liquid embolic composition into the syringe barrel. The sliding member is then moved so that the threaded bore is aligned with the syringe plunger for delivery of the liquid embolic composition. The syringe is then connected to a catheter in preparation for delivery of the composition to the vascular site. Alternatively, the syringe may be formed with an attached catheter.
A distal end of a delivery catheter is positioned at the vascular site in a known manner either before or after attachment of the syringe. The embolizing composition is then injected by rotating the syringe handle. Injection of the embolizing composition forms a nidus of embolizing composition within the vascular site. Delivery of the embolizing composition is continued under known visualization techniques for a period of time or until embolization of the vascular site is complete. The injection of the embolizing composition is then halted by stopping the rotation of the syringe handle and also by sliding the sliding member so that the plunger is aligned with the unthreaded bore and pressure is released from the embolizing composition in the syringe. In the event that it is determined that additional embolizing composition is required at the vascular site, the sliding member may be moved back to position the threaded bore aligned with the plunger and delivery of the embolizing composition may be continued. The sliding member allows delivery to be stopped and started precisely any number of times until embolization is complete.
While the invention has been described in detail with reference to the preferred various changes and modifications can be made and equivalents employed, without departing from the present invention.
This application is a continuation-in-part of U.S. patent application Ser. No. 09/574,500 filed on May 19, 2000 now U.S. Pat. No. 6,645,167 which claims benefit of U.S. Provisional Patent Application Ser. No. 60/135,222 filed May 21, 1999, and U.S. Provisional Patent Application Ser. No. 60/135,289 filed May 21, 1999, which are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4200804 | Farella et al. | Apr 1980 | A |
4244366 | Raines | Jan 1981 | A |
4710179 | Haber et al. | Dec 1987 | A |
4938763 | Dunn et al. | Jul 1990 | A |
4944726 | Hilal et al. | Jul 1990 | A |
4983585 | Pennell et al. | Jan 1991 | A |
5068225 | Pennell et al. | Nov 1991 | A |
5084017 | Maffetone | Jan 1992 | A |
RE33821 | Banks | Feb 1992 | E |
5116615 | Gokcen et al. | May 1992 | A |
5147294 | Smith et al. | Sep 1992 | A |
5250030 | Corsich | Oct 1993 | A |
5256144 | Kraus et al. | Oct 1993 | A |
5324263 | Kraus et al. | Jun 1994 | A |
5385561 | Cerny | Jan 1995 | A |
5389076 | Shaw | Feb 1995 | A |
5433216 | Sugrue et al. | Jul 1995 | A |
5466680 | Rudy | Nov 1995 | A |
5469867 | Schmitt | Nov 1995 | A |
5526809 | Fiddian-Green | Jun 1996 | A |
5540657 | Kurjan et al. | Jul 1996 | A |
5561134 | Spada et al. | Oct 1996 | A |
5580568 | Greff et al. | Dec 1996 | A |
5582167 | Joseph | Dec 1996 | A |
5611783 | Mikkelsen | Mar 1997 | A |
5618273 | Fischer | Apr 1997 | A |
5650447 | Keefer et al. | Jul 1997 | A |
5651980 | Lanza et al. | Jul 1997 | A |
5652366 | Spada et al. | Jul 1997 | A |
5661171 | Acharya | Aug 1997 | A |
5667767 | Greff et al. | Sep 1997 | A |
5695480 | Evans et al. | Dec 1997 | A |
5731338 | Acharya | Mar 1998 | A |
5736554 | Spada et al. | Apr 1998 | A |
5741275 | Wyssmann | Apr 1998 | A |
5741805 | Acharya | Apr 1998 | A |
5749968 | Melanson et al. | May 1998 | A |
5776096 | Fields | Jul 1998 | A |
5800373 | Melanson et al. | Sep 1998 | A |
5819723 | Joseph | Oct 1998 | A |
5824703 | Clark, Jr. | Oct 1998 | A |
5826584 | Schmitt | Oct 1998 | A |
5830178 | Jones et al. | Nov 1998 | A |
5844016 | Sawhney et al. | Dec 1998 | A |
5851508 | Greff et al. | Dec 1998 | A |
5888546 | Ji et al. | Mar 1999 | A |
5891477 | Lanza et al. | Apr 1999 | A |
5894022 | Ji et al. | Apr 1999 | A |
5902796 | Shand et al. | May 1999 | A |
5910104 | Dobak, III et al. | Jun 1999 | A |
5912005 | Lanza et al. | Jun 1999 | A |
5945102 | de Faire et al. | Aug 1999 | A |
5952351 | Evans et al. | Sep 1999 | A |
5958406 | de Faire et al. | Sep 1999 | A |
5964223 | Baran | Oct 1999 | A |
5981698 | Brittain | Nov 1999 | A |
6030612 | de Faire et al. | Feb 2000 | A |
6090945 | Audia et al. | Jul 2000 | A |
6096763 | Hoffman et al. | Aug 2000 | A |
6099499 | Ciamacco, Jr. | Aug 2000 | A |
6117142 | Goodson et al. | Sep 2000 | A |
6121341 | Sawhney et al. | Sep 2000 | A |
6126936 | Lanza et al. | Oct 2000 | A |
6130200 | Brodbeck et al. | Oct 2000 | A |
6171298 | Matsuura et al. | Jan 2001 | B1 |
6183461 | Matsuura et al. | Feb 2001 | B1 |
6258819 | Clark et al. | Jul 2001 | B1 |
6261582 | Needham et al. | Jul 2001 | B1 |
6287558 | Lanza et al. | Sep 2001 | B1 |
6291528 | Scott | Sep 2001 | B1 |
6296847 | Gokcen et al. | Oct 2001 | B1 |
6307054 | Truesdale et al. | Oct 2001 | B1 |
6331311 | Brodbeck et al. | Dec 2001 | B1 |
6335384 | Evans et al. | Jan 2002 | B1 |
6368612 | Lanza et al. | Apr 2002 | B1 |
6376500 | Clark et al. | Apr 2002 | B1 |
6387977 | Sawhney et al. | May 2002 | B1 |
Number | Date | Country |
---|---|---|
0 291 177 | Apr 1988 | EP |
WO 9003768 | Apr 1990 | WO |
WO 9804312 | Feb 1998 | WO |
WO 9920326 | Apr 1999 | WO |
0071196 | Nov 2000 | WO |
Number | Date | Country | |
---|---|---|---|
20030055386 A1 | Mar 2003 | US |
Number | Date | Country | |
---|---|---|---|
60135289 | May 1999 | US | |
60135222 | May 1999 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09574500 | May 2000 | US |
Child | 10222478 | US |